

Press Release Monday, September 29, 2014 Strides Arcolab Limited, Strides House, Bannerghatta Road, Bangalore – 560076, India

BSE: 532531 NSE: STAR

Strides Arcolab announces strategic Investor for its greenfield Biotech project

Bangalore, September 29, 2014: Strides Arcolab Limited ("Strides") today announced that it has entered into an agreement with GMS Holdings ("GMS") whereby GMS will invest USD 21.90 Million for a 25.1% stake in Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides, to fund its Greenfield project. The transaction is expected to close in Q4 of 2014 and is subject to customary closing conditions, regulatory and corporate approvals, as may be required.

Transaction details

- Strides has invested USD 16.9 Million in Stelis to date.
- Strides and GMS will invest an amount of USD 61.9 Million taking total equity investment in Stelis to USD 78.8 Million
- GMS to invest USD 8.5 Million for a 25.1% stake in Stelis on closing, at a premium of 50% of the current equity investment by Strides.
- Further equity infusion of USD 40 Million by Strides and USD 13.40 Million by GMS to be in tranches based on project and product development needs over a period of 2 years, in proportion to their ownership at par.
- Stelis also has in place, a project credit line of USD 40 Million
- With the total equity infusion of USD 78.8 Million and credit line of USD 40 Million, no further funding will be required till commercialization

Commenting on the transaction, Joe Thomas, Chief Corporate Development Officer of Strides and Head – Biotech division stated, "We are extremely pleased to have GMS Holdings as our strategic partner for the emerging Biotech business. GMS Holdings has a track record of having partnered in successful businesses, with a strong presence in the MENA region. This partnership will accelerate our emerging market strategy for the biotech business"

Commenting on the occasion, Ghiath Sukhtian, Chairman of GMS Holdings stated "We are delighted to be partnering with Strides on this exciting venture. Strides has a long track record of building successful pharma platforms and we believe that by joining our efforts on this investment we can create significant value for both our groups."



About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products.

The Company has 8 manufacturing facilities presence in more than 75 countries in developed and emerging markets.

Additional information is available at the Company's website at www.stridesarco.com.

About GMS Holdings

GMS Holdings is a privately owned investment company, based in Jordan that actively manages a diversified group of assets around the world. The company's investments include businesses that operate in various sectors, including pharmaceuticals, telecommunications, specialized contracting, oil-field services, agriculture and realestate.

GMS Holdings has a long track record of investing in and growing successful pharmaceutical ventures. In the MENA region, GMS Holdings has contributed to the growth of a number of leading local and regional pharmaceutical companies, including MS Pharma, a regional pharmaceutical company based in Jordan, and Tabuk Pharmaceuticals, a subsidiary of Astra Industrial Group based in Saudi Arabia.

GMS Holdings has also participated in the growth of international pharmaceutical ventures including Alvogen, a company which it co-founded in 2007 and exited earlier this year.



For further information, please contact:

<u>Strides</u>	PR Consultancy
Joe Thomas, Chief Corporte Develoment Officer &	Weber Shandwick
Head – Biotech Division	Kaveri Mandanna: +91 90089 59697
+91 80 6784 0119	<u>KMandanna@webershandwick.com</u>
Vikesh Kumar +91 80 6784 0827	Mahesh Nair: +91 98803 76648
Kannan. N: +91 98450 54745	MNair@webershandwick.com

